RÉSUMÉ
OBJECTIVE: Seizures are common in critically ill children and neonates, and these patients would benefit from intravenous (IV) antiseizure medications with few adverse effects. We aimed to assess the safety profile of IV lacosamide (LCM) among children and neonates. METHODS: This retrospective multicenter cohort study examined the safety of IV LCM use in 686 children and 28 neonates who received care between January 2009 and February 2020. RESULTS: Adverse events (AEs) were attributed to LCM in only 1.5% (10 of 686) of children, including rash (n = 3, .4%), somnolence (n = 2, .3%), and bradycardia, prolonged QT interval, pancreatitis, vomiting, and nystagmus (n = 1, .1% each). There were no AEs attributed to LCM in the neonates. Across all 714 pediatric patients, treatment-emergent AEs occurring in >1% of patients included rash, bradycardia, somnolence, tachycardia, vomiting, feeling agitated, cardiac arrest, tachyarrhythmia, low blood pressure, hypertension, decreased appetite, diarrhea, delirium, and gait disturbance. There were no reports of PR interval prolongation or severe cutaneous adverse reactions. When comparing children who received a recommended versus a higher than recommended initial dose of IV LCM, there was a twofold increase in the risk of rash in the higher dose cohort (adjusted incidence rate ratio = 2.11, 95% confidence interval = 1.02-4.38). SIGNIFICANCE: This large observational study provides novel evidence demonstrating the tolerability of IV LCM in children and neonates.
Sujet(s)
Anticonvulsivants , Enfant hospitalisé , Nouveau-né , Humains , Enfant , Lacosamide , Anticonvulsivants/effets indésirables , Études de cohortes , Bradycardie/induit chimiquement , Bradycardie/épidémiologie , Envie de dormir , Acétamides/effets indésirables , Résultat thérapeutique , Études rétrospectivesRÉSUMÉ
OBJECTIVE: The objective of this study is to evaluate the safety and tolerability of intravenous (IV) lacosamide infusion in patients aged ≥1 month to <17 years with epilepsy. METHODS: This Phase 2/3 open-label trial (EP0060; NCT02710890) enrolled patients in two age cohorts (cohort 1: ≥8 to <17 years; cohort 2: ≥1 month to <8 years). Eligible patients were receiving oral lacosamide as adjunctive treatment or monotherapy (in an open-label long-term trial or by prescription) or were not receiving lacosamide before enrolment. Patients initiated IV lacosamide (2-12 mg/kg/day or 100-600 mg/day; 15-60 minutes infusion) as a replacement for oral lacosamide or as adjunctive treatment. The primary outcomes were treatment-emergent adverse events (TEAEs) and discontinuations due to TEAEs. RESULTS: In total, 103 patients were enrolled and completed the trial; 55 patients were included in cohort 1 (≥8 to <17 years), 48 in cohort 2 (≥1 month to <8 years). During the 4 weeks before screening, 74 (71.8%) patients had focal seizures, 12 (11.7%) had generalized seizures, and two (1.9%) had unclassified seizures. Most patients (74 [71.8%]) initiated lacosamide as adjunctive IV treatment. The mean overall duration of exposure to IV lacosamide was 1.18 days. Seventy-nine (76.7%) patients had one IV lacosamide infusion, 20 (19.4%) had two, one (1.0%) had three, and three (2.9%) had 10 infusions. Overall, five (4.9%) patients had a total of seven TEAEs. The only TEAEs reported in two or more patients were increased blood triglycerides (two [1.9%]). No serious or severe TEAEs were reported, and no patients discontinued due to TEAEs. No TEAEs were considered drug-related by the investigator. No consistent or clinically relevant treatment-related changes from baseline were observed for hematology, clinical chemistry parameters, vital signs, or 12-lead electrocardiograms. SIGNIFICANCE: IV lacosamide was generally well tolerated in pediatric patients (≥1 month to <17 years) with epilepsy, and no new safety concerns were identified.
Sujet(s)
Anticonvulsivants , Épilepsie , Enfant , Humains , Acétamides/effets indésirables , Anticonvulsivants/usage thérapeutique , Épilepsie/traitement médicamenteux , Lacosamide/usage thérapeutique , Crises épileptiques/traitement médicamenteuxRÉSUMÉ
This Phase III, long-term, open-label extension (OLE) trial (EP0009; NCT01832038) was conducted to evaluate the long-term safety, tolerability, and efficacy of adjunctive lacosamide (100-400 mg/day) in Chinese and Japanese people with epilepsy (PWE) (16-70 years) who had completed a double-blind, randomized, placebo-controlled trial of adjunctive lacosamide (EP0008; NCT01710657). PWE entered the OLE trial on 200 mg/day lacosamide and up to 3 concomitant antiseizure medications. Dose adjustments were permitted to optimize tolerability and seizure reduction. Safety variables were treatment-emergent adverse events (TEAEs) and discontinuations due to TEAEs. Efficacy variables were percent change in focal seizure frequency per 28 days from Baseline of the double-blind trial, ≥50 % and ≥75 % responder rates, seizure-freedom, and proportion of PWE on lacosamide monotherapy. Overall, 473 PWE (74.0 % Chinese and 26.0 % Japanese) were enrolled; 238 (50.3 %) PWE completed the trial and 235 (49.7 %) discontinued, most commonly due to lack of efficacy (81 [17.1 %]), adverse events (55 [11.6 %]), and consent withdrawn (49 [10.4 %]). During the trial, PWE received lacosamide for a median of 1016.0 days (â¼3 years), with a total exposure of 1454.8 person-years; 321 (67.9 %) PWE received lacosamide for >24 months, and 246 (52.0 %) for >36 months. The median modal dose of lacosamide was 300 mg/day. Overall, 410/473 (86.7 %) PWE reported TEAEs, 244 (51.6 %) had a TEAE that was considered drug-related, and 49 (10.4 %) discontinued due to a TEAE. The most common TEAEs (≥20 % of PWE) were nasopharyngitis, dizziness, and upper respiratory tract infection. The median reduction in focal seizure frequency per 28 days from Baseline was 57.1 %, and the ≥50 % and ≥75 % responder rates were 57.1 % (269/471) and 29.7 % (140/471), respectively. Among PWE who completed 12, 24, and 36 months of treatment, the 12-, 24-, and 36-month seizure-freedom rates were 3.5 % (13/375), 3.4 % (11/321), and 2.0 % (5/247), respectively. Among PWE exposed to lacosamide for ≥6 months and ≥12 months, the proportions of PWE that maintained continuous monotherapy for ≥6 months and ≥12 months were 5.0 % (21/421) and 5.0 % (19/378), respectively. Overall, lacosamide was well-tolerated as long-term adjunctive therapy in Chinese and Japanese PWE and uncontrolled focal seizures, with improvements in seizure reduction maintained over 36 months of treatment.
Sujet(s)
Anticonvulsivants , Épilepsie , Adulte , Anticonvulsivants/effets indésirables , Chine , Méthode en double aveugle , Association de médicaments , Épilepsie/traitement médicamenteux , Humains , Japon , Lacosamide/usage thérapeutique , Crises épileptiques/induit chimiquement , Crises épileptiques/traitement médicamenteux , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: The existing staging systems of uterine leiomyosarcoma (uLMS) cannot classify the patients into four non-overlapping prognostic groups. This study aimed to develop a prediction model to predict the three-year survival status of uLMS. METHODS: In total, 201 patients with uLMS who had been treated between June 1993 and January 2014, were analyzed. Potential prognostic indicators were identified by univariate models followed by multivariate analyses. Prediction models were constructed by binomial regression with 3-year survival status as a binary outcome, and the final model was validated by internal cross-validation. RESULTS: Nine potential parameters, including age, log tumor diameter, log mitotic count, cervical involvement, parametrial involvement, lymph node metastasis, distant metastasis, tumor circumscription and lymphovascular space invasion were identified. 110 patients had complete data to build the prediction models. Age, log tumor diameter, log mitotic count, distant metastasis, and circumscription were significantly correlated with the 3-year survival status. The final model with the lowest Akaike's Information Criterion (117.56) was chosen and the cross validation estimated prediction accuracy was 0.745. CONCLUSION: We developed a prediction model for uLMS based on five readily available clinicopathologic parameters. This might provide a personalized prediction of the 3-year survival status and guide the use of adjuvant therapy, a cancer surveillance program, and future studies.
RÉSUMÉ
OBJECTIVE: To evaluate efficacy and tolerability of adjunctive lacosamide in children and adolescents with uncontrolled focal (partial-onset) seizures. METHODS: In this double-blind trial (SP0969; NCT01921205), patients (age ≥4-<17 years) with uncontrolled focal seizures were randomized (1:1) to adjunctive lacosamide/placebo. After a 6-week titration, patients who reached the target dose range for their weight (<30 kg: 8-12 mg/kg/d oral solution; ≥30-<50 kg: 6-8 mg/kg/d oral solution; ≥50 kg: 300-400 mg/d tablets) entered a 10-week maintenance period. The primary outcome was change in focal seizure frequency per 28 days from baseline to maintenance. RESULTS: Three hundred forty-three patients were randomized; 306 (lacosamide 152 of 171 [88.9%]; placebo 154 of 172 [89.5%]) completed treatment (titration and maintenance). Adverse events (AEs) were the most common reasons for discontinuation during treatment (lacosamide 4.1%; placebo 5.8%). From baseline to maintenance, percent reduction in focal seizure frequency per 28 days for lacosamide (n = 170) vs placebo (n = 168) was 31.7% (p = 0.0003). During maintenance, median percent reduction in focal seizure frequency per 28 days was 51.7% for lacosamide and 21.7% for placebo. Fifty percent responder rates (≥50% reduction) were 52.9% and 33.3% (odds ratio 2.17, p = 0.0006). During treatment, treatment-emergent AEs were reported by 67.8% lacosamide-treated patients (placebo 58.1%), most commonly (≥10%) somnolence (14.0%, placebo 5.2%) and dizziness (10.5%, placebo 3.5%). CONCLUSIONS: Adjunctive lacosamide was efficacious in reducing seizure frequency and generally well tolerated in patients (age ≥4-<17 years) with focal seizures. CLINICALTRIALSGOV IDENTIFIER: NCT01921205. CLASSIFICATION OF EVIDENCE: This trial provides Class I evidence that for children and adolescents with uncontrolled focal seizures, adjunctive lacosamide reduces seizure frequency.
Sujet(s)
Anticonvulsivants/administration et posologie , Lacosamide/administration et posologie , Crises épileptiques/diagnostic , Crises épileptiques/traitement médicamenteux , Adolescent , Anticonvulsivants/sang , Enfant , Enfant d'âge préscolaire , Méthode en double aveugle , Association de médicaments , Femelle , Humains , Lacosamide/sang , Mâle , Études prospectives , Crises épileptiques/sang , Résultat thérapeutiqueRÉSUMÉ
We examined the effect of gender, age, and drug properties on liver events reporting frequency (RF) to assess patient- and drug-related risks for drug-induced liver injury (DILI). We performed a data-mining analysis of the WHO VigiBase™ to 1) identify drugs with gender- and age-biased RF and 2) characterize drug properties using the Liver Toxicity Knowledge Base. Age-, gender-specific Empirical Bayes Geometric Mean of relative reporting ratio of liver events with 90% confidence interval (CI) was calculated for 375 drugs with DILI potential. Forty-one drugs showed an increased RF in women, which had a higher prevalence of reactive metabolite formation and mitochondrial dysfunction and transporter inhibition. Fifty-nine drugs showed an increased RF in younger women (<50â¯yrs), many of which had a signature pattern of hepatocellular injury. In contrast, half of 17 drugs that showed an increased RF in men had a cholestatic pattern. In the older group (≥50â¯yrs), 17 drugs showed an increased RF and had higher transporter inhibition, Cmax, and plasma protein binding, yet shorter plasma elimination. Specific drug properties were associated with gender- and age-biased liver events RF, suggesting possible interactions of drug properties, gender, and age in DILI development.
Sujet(s)
Systèmes de signalement des effets indésirables des médicaments/statistiques et données numériques , Lésions hépatiques dues aux substances , Facteurs âges , Bases de données factuelles , Femelle , Humains , Mâle , Adulte d'âge moyen , Préparations pharmaceutiques/composition chimique , Préparations pharmaceutiques/métabolisme , Facteurs sexuelsRÉSUMÉ
AIMS: Accurate mitosis counting, which is important in the diagnosis of uterine smooth muscle tumours (USMTs), is often difficult and subjective. The mitosis-specific immunohistochemical marker phosphohistone-H3 (PHH3) has been shown to be diagnostically useful, but its expression, in relation to outcome, has not been thoroughly investigated. The aim of this study is to evaluate PHH3 as a diagnostic and prognostic marker in USMTs. METHODS AND RESULTS: PHH3 expression was evaluated in 55 leiomyosarcomas (LMSs), 26 smooth muscle tumours of uncertain malignant potential (STUMPs), 18 leiomyomas with bizarre nuclei (LBN), and 12 leiomyomas (LMs). Scores were expressed as counts per 10 high-power fields (HPFs). Median follow-up durations of patients with LMS, STUMP, LBN and LM were, respectively, 39, 78, 65.5 and 49.5 months. Twenty-eight patients with LMSs (50.9%) died, and two (7.7%) patients with STUMPs experienced recurrence. The median PHH3 scores for LMSs were significantly higher than those for other categories of tumour. A score of ≥29/10 HPFs was also independently associated with a poor outcome. To test whether the PHH3 score could distinguish between benign USMTs with atypical histology and those that were clinically malignant, two biological groups were further delineated. Patients in group 1 (18 LBNs and 24 STUMPs) all had an uneventful outcome, whereas patients in group 2 (two recurrent STUMPs and 32 LMSs) all had a recurrence or tumour-related death. Median PHH3 scores for the two groups were, respectively, 2/10 HPFs and 27/10 HPFs. A PHH3 score of ≥7/10 HPFs was highly associated with malignancy. CONCLUSION: PHH3 is useful in evaluation of the biological behaviour of USMTs, and may serve as a prognostic indicator for LMSs.
Sujet(s)
Marqueurs biologiques tumoraux/analyse , Histone/biosynthèse , Tumeur du muscle lisse/anatomopathologie , Tumeurs de l'utérus/anatomopathologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Aire sous la courbe , Femelle , Histone/analyse , Humains , Estimation de Kaplan-Meier , Adulte d'âge moyen , Mitose , Récidive tumorale locale/anatomopathologie , Pronostic , Modèles des risques proportionnels , Courbe ROC , Sensibilité et spécificité , Tumeur du muscle lisse/mortalité , Tumeurs de l'utérus/mortalitéRÉSUMÉ
Polypharmacy is common, and may modify mechanisms of drug-induced liver injury. We examined the effect of these drug-drug interactions on liver safety reports of four drugs highly associated with hepatotoxicity. In the WHO VigiBase™, liver event reports were examined for acetaminophen, isoniazid, valproic acid, and amoxicillin/clavulanic acid. Then, we evaluated the liver event reporting frequency of these 4 drugs in the presence of co-reported medications. Each of the 4 primary drugs was reported as having more than 2000 liver events, and co-reported with more than 600 different medications. Overall, the effect of 2275 co-reported drugs (316 drug classes) on the reporting frequency was analyzed. Decreased liver event reporting frequency was associated with 245 drugs/122 drug classes, including anti-TNFα, opioids, and folic acid. Increased liver event reporting frequency was associated with 170 drugs/82 drug classes; in particular, halogenated hydrocarbons, carboxamides, and bile acid sequestrants. After adjusting for age, gender, and other co-reported drug classes, multiple co-reported drug classes were significantly associated with decreased/increased liver event reporting frequency in a drug-specific/unspecific manner. In conclusion, co-reported medications were associated with changes in the liver event reporting frequency of drugs commonly associated with hepatotoxicity, suggesting that comedications may modify drug hepatic safety.
Sujet(s)
Systèmes de signalement des effets indésirables des médicaments/statistiques et données numériques , Lésions hépatiques dues aux substances , Interactions médicamenteuses , Acétaminophène/effets indésirables , Association amoxicilline-clavulanate de potassium/effets indésirables , Lésions hépatiques dues aux substances/étiologie , Fouille de données , Bases de données factuelles , Isoniazide/effets indésirables , Acide valproïque/effets indésirables , Organisation mondiale de la santéRÉSUMÉ
BACKGROUND/AIMS: Age-differences in the frequency and manifestations of drug-induced liver injury are not fully characterized. Data-mining analyses were performed to assess the impact of age on liver event reporting frequency with different phenotypes and agents. METHODS: 236 drugs associated with hepatotoxicity were evaluated using the Empirical Bayes Geometric Mean (EBGM) of the relative reporting ratio with 90% confidence interval (EB05 and EB95) calculated for the age groups: 0-17, 18-64, and⩾65years (or elderly), for overall, serious (acute liver failure), hepatocellular, and cholestatic liver injury, using the WHO Safety Report Database. RESULTS: Overall, cases of age 0-17, 18-64, and 65years or older comprised 6%, 62%, and 32% of liver event reports. Acute liver failure and hepatocellular injury were more frequently reported among children compared to adults and the elderly while reports with cholestatic injury were more frequent among the elderly (p<0.00001). A potential to cause mitochondrial dysfunction was more prevalent among the drugs with increased pediatric reporting frequency while high lipophilicity and biliary excretion were more common among the drugs associated with higher reporting frequency in the elderly. CONCLUSION: Age-specific phenotypes and potential drug properties associated with age-specific hepatotoxicity were identified in reported liver events; further analyses are warranted.
Sujet(s)
Lésions hépatiques dues aux substances/épidémiologie , Effets secondaires indésirables des médicaments/épidémiologie , Adolescent , Adulte , Systèmes de signalement des effets indésirables des médicaments , Sujet âgé , Sujet âgé de 80 ans ou plus , Enfant , Enfant d'âge préscolaire , Fouille de données , Bases de données factuelles , Humains , Nourrisson , Nouveau-né , Foie/effets des médicaments et des substances chimiques , Adulte d'âge moyen , Organisation mondiale de la santé , Jeune adulteRÉSUMÉ
A statistical methodology--focused on temporal change detection--was developed to highlight excursions from baseline spontaneous adverse event (AE) reporting. We used regression (both smooth trend and seasonal components) to model the time course of a drug's reports containing an AE, and then compared the sum of counts in the past 2 months with the fitted trend. The signaling threshold was tuned, using retrospective analysis, to yield acceptable sensitivity and specificity. The method may enhance pharmacovigilance by providing effective automated alerting of reporting aberrations when databases are small, when drugs have established safety profiles, and/or when product quality issues are of concern.
Sujet(s)
Systèmes de signalement des effets indésirables des médicaments , Effets secondaires indésirables des médicaments , Traitement automatique des données/méthodes , Systèmes de signalement des effets indésirables des médicaments/normes , Humains , Études rétrospectives , Facteurs tempsRÉSUMÉ
Sturge-Weber syndrome (SWS) is a rare congenital neurocutaneous disorder that causes congenital glaucoma. Previous experiences have shown that drainage procedures are often required to control associated glaucoma. The conventional surgical approach in trabeculectomy carries a significant risk of intraoperative expulsive hemorrhage. Here, we describe a modified approach of the conventional trabeculectomy technique, which may lower the risk of expulsive hemorrhage. A viscoelastic device was employed to maintain a steady intraocular pressure throughout the procedure. Details of the surgical technique and material used are described. One patient with congenital glaucoma associated with SWS underwent a successful trabeculectomy using the modified technique. Postoperative intraocular pressure was successfully reduced and no intraoperative complications occurred. We describe a successful case of trabeculectomy in a SWS case where a modified technique was applied.
Sujet(s)
Glaucome/congénital , Pression intraoculaire , Syndrome de Sturge-Weber/complications , Trabéculectomie/méthodes , Humains , Nouveau-né , Mâle , Syndrome de Sturge-Weber/diagnostic , Syndrome de Sturge-Weber/chirurgie , Acuité visuelleRÉSUMÉ
UNLABELLED: We report a case of progressive capsule membrane growth 4 months after neodymium:YAG capsulotomy for posterior capsule opacification. The clinical picture closely resembled epithelial ingrowth, but histology proved otherwise. Multiple operations were required to control glaucoma and capsule proliferation. However, the patient's visual potential was limited by corneal decompensation and glaucomatous damage. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.
Sujet(s)
Opacification de la capsule postérieure/chirurgie , Oedème cornéen/étiologie , Glaucome/étiologie , Lasers à solide , Capsule du cristallin/anatomopathologie , Complications postopératoires , Sujet âgé , Antihypertenseurs/usage thérapeutique , Association thérapeutique , Oedème cornéen/traitement médicamenteux , Oedème cornéen/physiopathologie , Femelle , Glaucome/traitement médicamenteux , Glaucome/physiopathologie , Glaucome/chirurgie , Implants de drainage du glaucome , Gonioscopie , Humains , Pression intraoculaire , Thérapie laser , Pose d'implant intraoculaire , Phacoémulsification , Capsule postérieure du cristallin/chirurgie , Acuité visuelle/physiologieRÉSUMÉ
Drug induced liver injury during drug development is evidenced by a higher incidence of serum alanine aminotransferase (ALT) elevations in treated versus placebo populations and termed an "ALT signal". We sought to quantify whether an ALT signal in pre-marketing clinical trials predicted post-marketing hepatotoxicity. Incidence of ALT elevations (ALT ≥ 3 times upper limits normal [× ULN]) for drug and placebo of new chemical entities and approved drugs associated with hepatotoxicity was calculated using the Food and Drug Administration (FDA) website. Post-marketing liver safety events were identified using the FDA Adverse Event Reporting System (AERS). The association of FDA AERS signal score (EB05 ≥ 2) and excess risk of pre-marketing ALT elevation (difference in incidence of ALT ≥ 3× ULN in treated versus placebo) was examined. An ALT signal of ≥ 1.2% was significantly associated with a post-marketing liver safety signal (p ≤ 0.013) and a 71.4% positive predictive value. An absent ALT signal was associated with a high likelihood of post-marketing liver safety; negative predictive value of 89.7%. Daily drug dose information improved the prediction of post-marketing liver safety. A cut-off of 1.2% increase in ALT ≥ 3× ULN in treated versus placebo groups provides an easily calculated method for predicting post-marketing liver safety.
Sujet(s)
Alanine transaminase/sang , Lésions hépatiques dues aux substances/sang , Surveillance post-commercialisation des produits de santé , Lésions hépatiques dues aux substances/étiologie , Agrément de médicaments , Effets secondaires indésirables des médicaments , Humains , États-Unis , Food and Drug Administration (USA)RÉSUMÉ
PURPOSE: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are medically serious skin reactions that are often drug induced. The mainstay of therapy and future prevention is to discontinue and avoid the use of the suspected inducing drug. However, many cases of SJS/TEN occur in patients who are taking multiple medications, and it is often difficult to determine which drug to stop. This analysis was conducted to identify drugs that were most associated with SJS/TEN in the US Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) database and to identify medications that were likely innocent bystanders. METHODS: A Multi-item Gamma Poisson Shrinker value with an EB05 ≥ 2 was considered a disproportional increase in reporting frequency (at least two times higher than expected). The identified drugs with reporting frequency of SJS/TEN in the US FDA AERS database were then compared to the EuroSCAR (European case-control surveillance of severe cutaneous adverse reactions) study results as a reference to define signals. The EB05s were calculated as a cumulative relative reporting frequency from 1968 to 3Q2009. RESULTS: Fifty drugs were identified as being associated with SJS/TEN. This included 12 "highly suspect" drugs and 36 "suspect" drugs. Meloxicam was the only drug that appeared on the "highly suspect" list from EuroSCAR that did not show a disproportional increase in relative reporting frequency (EB05 = 0.734). In addition, several drugs did not have an association with SJS/TEN (EB05 < 2). CONCLUSIONS: There was good concordance between the reporting frequencies observed in the FDA AERS database and the published risk estimation of medications implicated in SJS/TEN.
Sujet(s)
Systèmes de signalement des effets indésirables des médicaments/statistiques et données numériques , Effets secondaires indésirables des médicaments , Effets secondaires indésirables des médicaments/induit chimiquement , Syndrome de Stevens-Johnson/induit chimiquement , Syndrome de Stevens-Johnson/étiologie , Bases de données factuelles , Effets secondaires indésirables des médicaments/épidémiologie , Humains , Modèles logistiques , Syndrome de Stevens-Johnson/épidémiologieRÉSUMÉ
Drug toxicity is a major cause of late-stage product attrition. During lead identification and optimization phases little information is typically available about which molecules might have safety concerns. A system was built linking chemistry, preclinical and human safety information, enabling scientists to lever safety knowledge across multiple disciplines. The system consists of a data warehouse with chemical structures and chemical and biological properties for â¼80000 compounds and tools to access and analyze clinical data, toxicology, in vitro pharmacology and drug metabolism data. Tapping into this safety knowledge enables rapid clinically focused risk assessments of drug candidates. Use of this strategy adds value to the drug discovery process at GSK via efficient triage of compounds based on their potential for toxicity.
Sujet(s)
Conception de médicament , Découverte de médicament/méthodes , Industrie pharmaceutique/méthodes , Animaux , Bases de données factuelles , Évaluation préclinique de médicament/méthodes , Effets secondaires indésirables des médicaments , Humains , Préparations pharmaceutiques/composition chimique , Préparations pharmaceutiques/métabolisme , Appréciation des risques/méthodes , Toxicologie/méthodesRÉSUMÉ
We evaluated the effectiveness of diode laser trans-scleral cyclophotocoagulation (TSCPC) on intraocular pressure (IOP) in nine patients having raised IOP following use of silicone oil (SO) for retinal detachment (RD) surgery in a retrospective observational case series. Diode laser TSCPC was applied at a power setting of 1.75 to 2.5 watts, for two sec with a maximum of 30 applications. The patients were followed up for 40 to 312 weeks. The mean pre-laser IOP was 32.06 mm Hg (SD 7.32). The mean post-laser IOP at one month, three months and six months was 17.89 mm Hg (SD 8.23), 21.89 mm Hg (SD 8.16) and 21.67 mm Hg (SD 7.55) respectively. The final IOP (at the last follow-up) was 19.56 mm Hg (SD 7.85) (P=0.021). Seven of them had undergone SO removal. In our observation, effectiveness of TSCPC in long-term control of SO-induced ocular hypertension was limited as compared to short-term control of IOP.
Sujet(s)
Asiatiques , Coagulation par laser/méthodes , Lasers à semiconducteur/usage thérapeutique , Hypertension oculaire/induit chimiquement , Hypertension oculaire/chirurgie , Huiles de silicone/effets indésirables , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Pression intraoculaire , Mâle , Adulte d'âge moyen , Hypertension oculaire/ethnologie , Hypertension oculaire/physiopathologie , Sclère/chirurgieRÉSUMÉ
BACKGROUND: Challenges exist in the clinical diagnosis of drug-induced liver injury (DILI) and in obtaining information on hepatotoxicity in humans. OBJECTIVE: (i) To develop a unified list that combines drugs incriminated in well vetted or adjudicated DILI cases from many recognized sources and drugs that have been subjected to serious regulatory actions due to hepatotoxicity; and (ii) to supplement the drug list with data on reporting frequencies of liver events in the WHO individual case safety report database (VigiBase). DATA SOURCES AND EXTRACTION: (i) Drugs identified as causes of DILI at three major DILI registries; (ii) drugs identified as causes of drug-induced acute liver failure (ALF) in six different data sources, including major ALF registries and previously published ALF studies; and (iii) drugs identified as being subjected to serious governmental regulatory actions due to their hepatotoxicity in Europe or the US were collected. The reporting frequency of adverse events was determined using VigiBase, computed as Empirical Bayes Geometric Mean (EBGM) with 90% confidence interval for two customized terms, 'overall liver injury' and 'ALF'. EBGM of >or=2 was considered a disproportional increase in reporting frequency. The identified drugs were then characterized in terms of regional divergence, published case reports, serious regulatory actions, and reporting frequency of 'overall liver injury' and 'ALF' calculated from VigiBase. DATA SYNTHESIS: After excluding herbs, supplements and alternative medicines, a total of 385 individual drugs were identified; 319 drugs were identified in the three DILI registries, 107 from the six ALF registries (or studies) and 47 drugs that were subjected to suspension or withdrawal in the US or Europe due to their hepatotoxicity. The identified drugs varied significantly between Spain, the US and Sweden. Of the 319 drugs identified in the DILI registries of adjudicated cases, 93.4% were found in published case reports, 1.9% were suspended or withdrawn due to hepatotoxicity and 25.7% were also identified in the ALF registries/studies. In VigiBase, 30.4% of the 319 drugs were associated with disproportionally higher reporting frequency of 'overall liver injury' and 83.1% were associated with at least one reported case of ALF. CONCLUSIONS: This newly developed list of drugs associated with hepatotoxicity and the multifaceted analysis on hepatotoxicity will aid in causality assessment and clinical diagnosis of DILI and will provide a basis for further characterization of hepatotoxicity.
Sujet(s)
Systèmes de signalement des effets indésirables des médicaments/statistiques et données numériques , Lésions hépatiques dues aux substances/étiologie , Coopération internationale , Médicaments sur ordonnance/effets indésirables , Lésions hépatiques dues aux substances/épidémiologie , Contrôle des médicaments et des stupéfiants/statistiques et données numériques , Europe/épidémiologie , Humains , Retraits de médicaments pour raisons de sécurité/statistiques et données numériques , États-Unis/épidémiologie , Organisation mondiale de la santéRÉSUMÉ
BACKGROUND AND OBJECTIVE: After a single unilateral acute primary angle-closure glaucoma attack, retinal nerve fiber layer (RNFL) may be thinned. The current study measured the RNFL thickness using optical coherence tomography in eyes with normal visual fields after recovery from a single attack of acute primary angle-closure glaucoma. PATIENTS AND METHODS: Twenty-one patients and age-matched control subjects underwent optical coherence tomography scanning after recovery from a single unilateral acute primary angle-closure glaucoma attack. Data from the affected eyes, normal fellow eyes, and control subjects were compared. RESULTS: Average RNFL thickness was 91.3 +/- 16.4 microm in the affected eyes, 100.1 +/- 16.4 microm in the fellow eyes, and 100.2 +/- 16.7 microm in the control eyes. Significant thinning was present in the affected eyes compared to the fellow eyes (P = .001) and the control eyes (P = .04). CONCLUSION: RNFL thickness was found to be significantly thinner in the eyes with angle-closure glaucoma.
Sujet(s)
Glaucome à angle fermé/diagnostic , Neurofibres/anatomopathologie , Papille optique/anatomopathologie , Atteintes du nerf optique/diagnostic , Cellules ganglionnaires rétiniennes/anatomopathologie , Tomographie par cohérence optique/méthodes , Maladie aigüe , Sujet âgé , Études transversales , Femelle , Études de suivi , Glaucome à angle fermé/physiopathologie , Humains , Pression intraoculaire , Mâle , Adulte d'âge moyen , Atteintes du nerf optique/physiopathologieRÉSUMÉ
PURPOSE: To report a new adverse effect related to treatment with bimatoprost. METHOD: Case report. A 43-year-old Asian female with bilateral glaucoma was noticed to have bilateral deepening of upper lid sulcus 3 months after beginning treatment with bimatoprost 0.03%. RESULTS: Bimatoprost was discontinued due to cosmetic reasons, and there was improvement of the lid sulcus deepening bilaterally 4 weeks after stopping the drug. CONCLUSIONS: Deepening of upper lid sulcus is one of the adverse effects related to treatment with bimatoprost. This effect may be more prominent in Asians who have relatively full upper lid sulcus.